Withaferin-A inhibits colorectal cancer growth and metastasis by targeting the HSP90/HIF-1α/EMT axis

Withaferin-A 通过靶向 HSP90/HIF-1α/EMT 轴抑制结直肠癌的生长和转移。

阅读:2

Abstract

INTRODUCTION: Withaferin-A (WA) derived from natural products can inhibit the growth and metastasis of colorectal cancer (CRC) in vitro and in vivo. MATERIAL AND METHODS: WA effects on colorectal cancer cells were studied using HCT116 and SW480 lines. In vitro we used shRNA knockdown, plasmid overexpression, viability, proliferation, colony, migration, and invasion assays. And Xenograft and metastasis mouse models evaluated tumor growth and toxicity. Molecular analysis used qRT-PCR, Western blot, IHC, immunoprecipitation, and RNA sequencing. RESULTS: Transcriptome analysis showed WA suppressed EMT, HSP90, and HIF-1α in CRC. WA inhibited HSP90, HIF-1α, E-cadherin, and their interaction. HIF-1α knockdown reduced CRC migration, invasion, and lung metastasis. 17-AAG similarly inhibited HSP90/HIF-1α and metastasis. HSP90 overexpression rescued HIF-1α expression, binding, and migratory ability in HIF-1α knockdown cells. CONCLUSIONS: These findings indicate that WA inhibits CRC's growth, migration, and invasion by inhibiting the HSP90/HIF-1α/EMT axis. And showed that WA could be a potential therapeutic agent for CRC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。